The repressive effect of NF-κB on p53 by mot-2 is involved in human keratinocyte transformation induced by low levels of arsenite

Toxicological Sciences

Volumn 116, Issue 1, 2010, Pages 174-182

  Li, Yuan ^a   Ling, Min ^a   Xu, Yuan ^a   Wang, Shoulin ^a   Li, Zhong ^a   Zhou, Jianwei ^a   Wang, Xinru ^a   Liu, Qizhan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aarsenic; DNA double strand breaks; Malignant transformation; Mot 2; Nuclear factor B; p53

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN MDM2; PROTEIN MOT 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; ARSENOUS ACID DERIVATIVE; HEAT SHOCK PROTEIN 70; HSPA9 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HACAT; CELL TRANSFORMATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE INTERACTION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; KERATINOCYTE; MALIGNANT TRANSFORMATION; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; TOXICITY;

ARSENITES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KERATINOCYTES; NF-KAPPA B; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; MITOCHONDRIAL PROTEINS;

EID: 77954353627     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq109     Document Type: Article

References (34)

1. Aylon, Y., and Oren, M. (2007). Living with p53, dying of p53. Cell 130, 597-600.
2. Bagla, P., and Kaiser, J. (1996). India's spreading health crisis draws global arsenic experts. Science 274, 174-175.
3. Bodwell, J.E., Kingsley, L.A., and Hamilton, J.W. (2004). Arsenic at very low concentrations alters glucocorticoid receptor (GR)-mediated gene activation but not GR-mediated gene repression: complex dose-response effects are closely correlated with levels of activated GR and require a functional GR DNA binding domain. Chem. Res. Toxicol. 17, 1064-1076.
4. Bukholm, I.K., and Nesland, J.M. (2000). Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 436, 224-228.
5. Chen, R., Qiu, W., Liu, Z., Cao, X., Zhu, T., Li, A., Wei, Q., and Zhou, J. (2007). Identification of JWA as a novel functional gene responsive to environmental oxidative stress induced by benzo[a]pyrene and hydrogen peroxide. Free Radic. Biol. Med. 42, 1704-1714.
6. Col, M., Col, C., Soran, A., Sayli, B.S., and Ozturk, S. (1999). Arsenic-related Bowen's disease, palmar keratosis, and skin cancer. Environ. Health Perspect. 107, 687-689.
7. Cox, A.D., and Der, C.J. (1994). Biological assays for cellular transformation. Methods Enzymol. 238, 277-294.
8. Guha Mazumder, D.N., Haque, R., Ghosh, N., De, B.K., Santra, A., Chakraborty, D., and Smith, A.H. (1998). Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int. J. Epidemiol. 27, 871-877.
9. Halazonetis, T.D., Gorgoulis, V.G., and Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355.
10. Hartwig, A., Blessing, H., Schwerdtle, T., and Walter, I. (2003). Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology 193, 161-169.
11. He, X.Q., Chen, R., Yang, P., Li, A.P., Zhou, J.W., and Liu, Q.Z. (2007). Biphasic effect of arsenite on cell proliferation and apoptosis is associated with the activation of JNK and ERK1/2 in human embryo lung fibroblast cells. Toxicol. Appl. Pharmacol. 220, 18-24.
12. Huang, C., Ke, Q., Costa, M., and Shi, X. (2004). Molecular mechanisms of arsenic carcinogenesis. Mol. Cell Biochem. 255, 57-66.
13. Huang, Y., Zhang, J., McHenry, K.T., Kim, M.M., Zeng, W., Lopez-Pajares, V., Dibble, C.C., Mizgerd, J.P., and Yuan, Z.M. (2008). Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res. 68, 9131-9136.
14. Karin, M. (2006). NF-κB and cancer: mechanisms and targets. Mol. Carcinog. 45, 355-361.
15. Kastan, M.B. (2007). Wild-type p53: tumors can't stand it. Cell 128, 837-840.
16. Kaul, S.C., Aida, S., Yaguchi, T., Kaur, K., and Wadhwa, R. (2005). Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem. 280, 39373-39379.
17. Konstantakou, E.G., Voutsinas, G.E., Karkoulis, P.K., Aravantinos, G., Margaritis, L.H., and Stravopodis, D.J. (2009). Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int. J. Oncol. 35, 401-416.
18. Li, J.J., Westergaard, C., Ghosh, P., and Colburn, N.H. (1997). Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res. 57, 3569-3576.
19. Lim do, Y., and Park, J.H. (2009). Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1060-G1068.
20. McLellan, F. (2002). Arsenic contamination affects millions in Bangladesh. Lancet 359, 1127.
21. Miho Matsui, C.N., Toyokuni, S., Takada, J., Akaboshi, M., Ishikawa, M., Imamura, S., and Miyachi, Y. (1999). The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen's disease. J. Invest. Dermatol. 113, 26-31.
22. Oscar Fernandez-Capetillo, A.L., Nussenzweig, M., and Nussenzweig, A. (2004). H2AX: the histone guardian of the genome. DNA Repair 3, 959-967.
23. Pi, J., Diwan, B.A., Sun, Y., Liu, J., Qu, W., He, Y., Styblo, M., and Waalkes, M.P. (2008). Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic. Biol. Med. 45, 651-658.
24. Pietsch, E.C., Sykes, S.M., McMahon, S.B., and Murphy, M.E. (2008). The p53 family and programmed cell death. Oncogene 27, 6507-6521.
25. Pott, W.A., Benjamin, S.A., and Yang, R.S. (2001). Pharmacokinetics, metabolism, and carcinogenicity of arsenic. Rev. Environ. Contam. Toxicol. 169, 165-214.
26. Prochazkova, J., Lichnovsky, V., Kylarova, D., Erdosova, B., and Vranka, P. (2004). Involvement of p53 and Bcl-2 family proteins in regulating programmed cell death and proliferation in human embryogenesis. Gen. Physiol. Biophys. 23, 209-229.
27. Shen, S., Lee, J., Weinfeld, M., and Le, X.C. (2008). Attenuation of DNA damage-induced p53 expression by arsenic: a possible mechanism for arsenic co-carcinogenesis. Mol. Carcinog. 47, 508-518.
28. Simeonova, P.P., and Luster, M.I. (2000). Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? J. Environ. Pathol. Toxicol. Oncol. 19, 281-286.
29. Soucy, N.V., Ihnat, M.A., Kamat, C.D., Hess, L., Post, M.J., Klei, L.R., Clark, C., and Barchowsky, A. (2003). Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 76, 271-279.
30. Tang, X., Zhu, Y., Han, L., Kim, A.L., Kopelovich, L., Bickers, D.R., and Athar, M. (2007). CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J. Clin. Invest. 117, 3753-3764.
31. Wadhwa, R., Taira, K., and Kaul, S.C. (2002). An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 7, 309-316.
32. Wadhwa, R., Takano, S., Mitsui, Y., and Kaul, S.C. (1999). NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. Cell Res. 9, 261-269.
33. Wen, G., Calaf, G.M., Partridge, M.A., Echiburu-Chau, C., Zhao, Y., Huang, S., Chai, Y., Li, B., Hu, B., and Hei, T.K. (2008). Neoplastic transformation of human small airway epithelial cells induced by arsenic. Mol. Med. 14, 2-10.
34. Yang, C., and Frenkel, K. (2002). Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 21, 331-342.